Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study

Overview

Journal J Health Econ Outcomes Res

Date 2025 Feb 10

PMID 39925364

Authors

Laurence Mainville

Helene Veillette

Paul R Fortin

Affiliations

Soon will be listed here.

Abstract

Prescription drug insurance in Canada is constituted of a patchwork of public and private insurance plans. The type of drug insurance may have a negative impact on access to treatment for patients covered by public plans compared with private plans. In patients with psoriasis treated with advanced therapy in public vs private drug insurance groups, we compared: (1) psoriasis severity scores when an advanced therapy was prescribed, (2) psoriasis severity scores at follow-up, (3) treatment response, and (4) delay between prescription and first dose of advanced therapy. This unicentric, retrospective cohort study included patients suffering from psoriasis treated by advanced therapy, dermatologist-prescribed between September 2015 and August 2019, in a tertiary academic care center in Québec City, Canada. Data were collected from medical records. Patients treated with an advanced therapy for psoriasis covered under the provincial public drug insurance plan (n = 78) and under a private drug plan (n = 93) did not differ regarding the studied outcomes. Patients' characteristics differed between groups. Patients in the public group were older ( < .0001), more socioeconomically deprived ( < .05), and more likely to benefit from compassion from the industry to access a prescribed medication free of charge ( < .0001) compared with patients from the privately insured group. The high prevalence of compassionate programs from the industry in the public insurance group (42% vs 14%), and the high prevalence of psoriasis on difficult-to-treat areas (face, genitalia, and/or palmoplantar areas) in our cohort (85.4%) may mask differences in access to advanced therapy between the two groups. Prescribers of advanced therapy can be reassured, as we found no inequality in access or care based on patients' drug insurance coverage.

References

Russell A, Olszynski W, Davison K, Koehn C, Haraoui B . Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy. Clin Rheumatol. 2009; 29(3):233-9. DOI: 10.1007/s10067-009-1338-1. View

Eissing L, Radtke M, Zander N, Augustin M . Barriers to guideline-compliant psoriasis care: analyses and concepts. J Eur Acad Dermatol Venereol. 2015; 30(4):569-75. DOI: 10.1111/jdv.13452. View

Buzney C, Peterman C, Saraiya A, Au S, Dumont N, Mansfield R . Clearance of psoriasis: the impact of private versus public insurance. J Drugs Dermatol. 2015; 14(2):119-25. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Park J, Hyun Rim J, Choe Y, Youn J . Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004; 50(4):582-4. DOI: 10.1016/s0190-9622(03)02793-2. View

Puzenat E, Bronsard V, Prey S, Gourraud P, Aractingi S, Bagot M . What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010; 24 Suppl 2:10-6. DOI: 10.1111/j.1468-3083.2009.03562.x. View

Paul C, Griffiths C, van de Kerkhof P, Puig L, Dutronc Y, Henneges C . Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2018; 80(1):70-79.e3. DOI: 10.1016/j.jaad.2018.06.039. View

Bhutani T, Wong J, Bebo B, Armstrong A . Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol. 2013; 149(6):717-21. DOI: 10.1001/jamadermatol.2013.133. View

Rumman A, Candia R, Sam J, Croitoru K, Silverberg M, Steinhart A . Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Can J Gastroenterol Hepatol. 2017; 2017:7365937. PMC: 5292380. DOI: 10.1155/2017/7365937. View

10.

Pampalon R, Hamel D, Gamache P, Raymond G . A deprivation index for health planning in Canada. Chronic Dis Can. 2009; 29(4):178-91. View

11.

Wakkee M, Thio H, Spuls P, de Jong E, Nijsten T . Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands. Br J Dermatol. 2008; 158(5):1159-61. DOI: 10.1111/j.1365-2133.2008.08512.x. View

12.

Spivak W, Sockolow R, Rigas A . The relationship between insurance class and severity of presentation of inflammatory bowel disease in children. Am J Gastroenterol. 1995; 90(6):982-7. View

13.

Meeuwis K, de Hullu J, de Jager M, Massuger L, van de Kerkhof P, van Rossum M . Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands. J Eur Acad Dermatol Venereol. 2010; 24(12):1425-30. DOI: 10.1111/j.1468-3083.2010.03663.x. View

14.

Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J . Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011; 15(4):210-9. DOI: 10.2310/7750.2011.10066. View

15.

Cifaldi M, Renaud J, Ganguli A, Halpern M . Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009. Curr Med Res Opin. 2016; 32(12):2029-2037. DOI: 10.1080/03007995.2016.1227775. View

16.

Takeshita J, Grewal S, Langan S, Mehta N, Ogdie A, Van Voorhees A . Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017; 76(3):377-390. PMC: 5731650. DOI: 10.1016/j.jaad.2016.07.064. View

17.

Ward M . Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. J Rheumatol. 2007; 34(10):2024-7. View

18.

Basra M, Fenech R, Gatt R, Salek M, Finlay A . The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008; 159(5):997-1035. DOI: 10.1111/j.1365-2133.2008.08832.x. View

19.

Ger T, Huang Y, Hui R, Tsai T, Chiu H . Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019; 10:2040622319843756. PMC: 6472156. DOI: 10.1177/2040622319843756. View

20.

Langley R, Feldman S, Nyirady J, van de Kerkhof P, Papavassilis C . The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2013; 26(1):23-31. DOI: 10.3109/09546634.2013.865009. View